Literature DB >> 24788194

Attitudes towards potentially carrying the FMR1 premutation: before vs after testing of non-carrier females with diminished ovarian reserve.

Lisa M Pastore1, Maria Antero, Karen Ventura, J Kim Penberthy, Semara A Thomas, Logan B Karns.   

Abstract

Diminished ovarian reserve (DOR) and premature ovarian failure are associated with elevated FMR1 CGG repeat alleles. We assessed pretest attitudes about potentially carrying the FMR1 premutation (FXP) (>55 CGG repeats) among reproductive age women compared with attitudes after learning their non-carrier status. Ninety-two women with DOR, regular menses and no family history of Fragile X Syndrome underwent FMR1 testing and completed attitudinal questionnaires before (T1) and 3 months after learning the test results (T2). The analysis utilized signed rank tests and α = 0.05. Very few women thought they were likely to have a FXP (6.6%). More participants thought FMR1 premutations were "serious" at T2 (62.9%) than at T1 (46.1%, p < 0.0003). When asked at T1 to "describe your feelings when you consider that you are potentially a carrier" of a FXP, 10% had negative feelings, 50% felt ambivalent, and 40% had positive feelings. At T2, feelings about not being a carrier were significantly more favorable (p < 0.0001): negative (0%), ambivalent (6.5%), positive (93%). Corroborating prior reports, few women had a negative view of FXP, perhaps anticipating that carrying the FXP explains their infertility. Perception of the seriousness of FXP increased after learning they did not carry the FXP, which would be predicted by health belief models.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24788194      PMCID: PMC5225992          DOI: 10.1007/s10897-014-9717-4

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  40 in total

1.  Premature ovarian failure (POF) and fragile X premutation females: from POF to to fragile X carrier identification, from fragile X carrier diagnosis to POF association data.

Authors:  M L Uzielli; S Guarducci; E Lapi; A Cecconi; U Ricci; G Ricotti; C Biondi; B Scarselli; F Vieri; P Scarnato; F Gori; A Sereni
Journal:  Am J Med Genet       Date:  1999-05-28

2.  Longitudinal study of the carrier testing process for fragile X syndrome: perceptions and coping.

Authors:  A McConkie-Rosell; G A Spiridigliozzi; J A Sullivan; D V Dawson; A M Lachiewicz
Journal:  Am J Med Genet       Date:  2001-01-01

3.  Attitudes toward fragile X mutation carrier testing from women identified in a general population survey.

Authors:  Aimee Anido; Lisa M Carlson; Stephanie L Sherman
Journal:  J Genet Couns       Date:  2007-02-13       Impact factor: 2.537

4.  Carrier testing in fragile X syndrome: effect on self-concept.

Authors:  A McConkie-Rosell; G A Spiridigliozzi; J A Sullivan; D V Dawson; A M Lachiewicz
Journal:  Am J Med Genet       Date:  2000-06-19

Review 5.  Prognostic assessment of ovarian reserve.

Authors:  R T Scott; G E Hofmann
Journal:  Fertil Steril       Date:  1995-01       Impact factor: 7.329

6.  Levels and associations among self-esteem, fertility distress, coping, and reaction to potentially being a genetic carrier in women with diminished ovarian reserve.

Authors:  Ceylan Cizmeli; Marci Lobel; Jason Franasiak; Lisa M Pastore
Journal:  Fertil Steril       Date:  2013-03-15       Impact factor: 7.329

7.  Fragile X AGG analysis provides new risk predictions for 45-69 repeat alleles.

Authors:  Sarah L Nolin; Sachin Sah; Anne Glicksman; Stephanie L Sherman; Emily Allen; Elizabeth Berry-Kravis; Flora Tassone; Carolyn Yrigollen; Amy Cronister; Marcia Jodah; Nicole Ersalesi; Carl Dobkin; W Ted Brown; Raghav Shroff; Gary J Latham; Andrew G Hadd
Journal:  Am J Med Genet A       Date:  2013-02-26       Impact factor: 2.802

Review 8.  The detection of diminished ovarian reserve in infertile women.

Authors:  F I Sharara; R T Scott; D B Seifer
Journal:  Am J Obstet Gynecol       Date:  1998-09       Impact factor: 8.661

9.  Fragile X syndrome: diagnostic and carrier testing.

Authors:  Stephanie Sherman; Beth A Pletcher; Deborah A Driscoll
Journal:  Genet Med       Date:  2005-10       Impact factor: 8.822

10.  Clinical significance of tri-nucleotide repeats in Fragile X testing: a clarification of American College of Medical Genetics guidelines.

Authors:  Kathryn E Kronquist; Stephanie L Sherman; Elaine B Spector
Journal:  Genet Med       Date:  2008-11       Impact factor: 8.822

View more
  3 in total

1.  Distribution of the FMR1 gene in females by race/ethnicity: women with diminished ovarian reserve versus women with normal fertility (SWAN study).

Authors:  Lisa M Pastore; Steven L Young; Ani Manichaikul; Valerie L Baker; Xin Q Wang; Joel S Finkelstein
Journal:  Fertil Steril       Date:  2016-11-02       Impact factor: 7.329

2.  Harms of Deception in FMR1 Premutation Genotype-Driven Recruitment.

Authors:  Sam Doernberg; Sara Chandros Hull
Journal:  Am J Bioeth       Date:  2017-04       Impact factor: 11.229

Review 3.  The FMR1 gene, infertility, and reproductive decision-making: a review.

Authors:  Lisa M Pastore; Joshua Johnson
Journal:  Front Genet       Date:  2014-07-07       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.